An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock — Robert F. Grover (1999) | RDL Network
An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock
Article 1999 en
Authors
RG
Robert F. Grover
DZ
David Zaccardelli
GC
Gene Colice
Abstract
1 min read
Treatment with the nitric oxide synthase inhibitor, 546C88, can restore the balance of vasomotor tone, thereby, maintaining blood pressure and reducing or eliminating the requirement for norepinephrine therapy in patients with septic shock. Infusion of 546C88 (1-20 mg/kg/hr) appears to have a satisfactory overall safety profile.
Junji Iwasaki, Mamdouh Afify, Christian Bleilevens, U. Klinge, Ralf Weiskirchen, Julia Steitz, Michael Vogt, Shintaro Yagi, Kazuyuki Nagai, Shinji Üemoto, René H. Tolba
Discussion(0)
No comments yet. Be the first to comment.